Table I.

Clinical characteristics of men with prostate cancer who were participants in the Health Professionals Follow-up Study and Physicians’ Health Study. PSA was measured at diagnosis. Gleason score was rereviewed with the modern classification system and, as a result, there were only four Gleason 5 scores and no Gleason 2–4 across the cohorts.

	HPFS (n = 347)	PHS (n = 276)
Age at diagnosis – median (Q1–Q3)	66.0 (62.0–70.0)	65.9 (62.2–69.8)
Lethal/metastatic events – n (%)	32 (9)	24 (9)
Years follow-up – median (Q1–Q3)	14.3 (12.0–16.8)	11.9 (9.3–15.6)
Gleason score – n(%)
2–6	51 (15)	74 (27)
3+4	132 (38)	97 (35)
4+3	102 (29)	57 (21)
8–10	62 (18)	48 (17)
Pathologic TNM stage – n(%)
T1/T2	224 (65)	170 (62)
T3/T4/N1	109 (31)	69 (25)
PSA ng/mL – n(%)
0–4	42 (12)	41 (15)
4–10	162 (47)	160 (58)
10–20	57 (16)	36 (13)
>20	40 (12)	14 (5)